Research Paper Volume 16, Issue 7 pp 6290—6313
Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma
Figure 7. Association of risk subgroup with therapy in LUAD patients. (A) KM survival analysis of TMB. (B) Effects of the risk score combined with TMB on the overall survival. (C, D) The survival status and immunotherapy reflection of patients in the high- and low-risk subgroups in three immunotherapy cohorts. Abbreviations: CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease. (E) Tumor mutation situations in different risk score subgroups. (F) The boxplot of sensitivity of common chemotherapy drugs between high- and low-risk subgroups.